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COST-EFFECTIVENESS OF EPLERENONE COMPARED WITH 
SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE AFTER 
ACUTE MYOCARDIAL INFARCTION
Inês M1, Soares M2, Vitorino R1
1Pﬁ zer Portugal, Porto Salvo, Oeiras, Portugal; 2University of York, York, Yorkshire, UK
OBJECTIVES: Aldosterone blockers (AB) are recommended for use in heart failure 
(HF) and HF post acute myocardial infarction (AMI) in patients with left ventricular 
dysfunction. Although only eplerenone is licensed for post-AMI HF treatment, less 
expensive spironolactone is used in some clinical settings. This study aims to evaluate 
cost-effectiveness of eplerenone compared with spironolactone in Portuguese patients 
with HF post-AMI. METHODS: A Markov model was developed to predict life-years 
(LY), quality adjusted life-years (QALY) and associated costs of AB treatment over 
patients life time. Estimates of all cause mortality relative risks were obtained via a 
meta-regression of AB published trials. Transition probabilities were derived from 
EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Survival 
Study), adjusted by a Weibull function with meta-regression estimates. AB adverse 
events (hyperkalemia, gynescomatia) rates were derived from a published meta-anal-
ysis. AB class effect was assumed regarding non-fatal hospitalization rates. Resource 
use and discontinuation rates were elicited through a panel of six cardiologists with 
extensive clinical experience. Unit costs and other cause mortality rate were extracted 
from Portuguese ofﬁ cial sources. Utilities were obtained using a regression model 
published in the literature derived from EPHESUS EQ-5D data. Societal perspective 
was adopted and both costs and effectiveness were discounted at 5%. RESULTS: 
Average cost per patient for eplerenone and spironolactone treatment were c25,907 
and c20,963, respectively. Average effectiveness gained with eplerenone was 0.44LY 
and 0.41QALY, meaning the incremental cost-effectiveness ratios were c11,309/LY 
and c12,040/QALY. Although indirect comparison of eplerenone with spironolactone 
introduces some uncertainty for relative effectiveness and cost-effectiveness: probabi-
listic sensitivity analysis revealed eplerenone to be cost-effective in 59% of Monte 
Carlo iterations at a willingness to pay of c35,000/QALY. CONCLUSIONS: Com-
pared with spironolactone, eplerenone treatment in patients with HF post-AMI is 
effective in reducing mortality, improving quality of life and is cost-effective by com-
monly used criteria in Portugal.
PCV70
COST SAVINGS OF ENOXAPARIN OVER UFH IN MEDICAL PATIENTS 
IN CANADIAN HOSPITAL SETTING
Wakeford C1, Mittmann N2
1sanoﬁ -aventis Canada Inc., Laval, QC, Canada; 2Sunnybrook Health Sciences Centre, 
Toronto, ON, Canada
OBJECTIVES: Enoxaparin, a low molecular weight heparin, was approved for use in 
medical patients in Canada in 2001, however, its use in hospitals has been relatively 
low. Low utilization is thought to be due to the perception by hospital administration 
of increased drug costs when compared to unfractionated heparin (UFH). Examination 
of the cost of clinical events for thromboprophylaxis has demonstrated that enoxapa-
rin may be cost savings. METHODS: A decision tree model was developed to the 
compare clinical results of four thromboprophylaxis regimens: enoxaparin 40 mg once 
daily, UFH 5000 International Units (IU) twice daily, UFH 5,000 IU three times daily 
and no prophylaxis. The main clinical outcomes in the model included DVT, PE, major 
bleeds, heparin-induced thrombocytopenia and death and were based on published 
literature Recurrences of the ﬁ rst four endpoints were also modelled. Canadian treat-
ment pattern data was based on one academic institution in Toronto, Canada. Costing 
(2010 Canadian $) for each state was also developed for direct medical costs. Within 
the model, parameters such as cost of thromboprophylaxis, number of patients, duration 
of treatment, length of stay, among many other variables were varied to reﬂ ect a hospital 
speciﬁ c analysis. RESULTS: When combining clinical and economic data in a Cana-
dian hospital setting, use of enoxaparin was cost-saving in a majority of situations. 
In the reference case, a typical hospital setting switching from UFH to enoxaparin 
resulted in an overall cost savings to the hospital, wherein a population of 1000 annual 
medical patients would realize a savings of $90,000CAD. Sensitivity analysis showed 
that enoxaparin was not cost savings when medically ill patients did not receive any 
thromboprophylaxis. CONCLUSIONS: Enoxaparin is a clinically safe and efﬁ cacious 
thromboprophylaxis regimen in medically ill patients. The model and follow-up analysis 
demonstrate that it is also a cost-saving choice of thromboprophylaxis within the 
Canadian hospital setting.
PCV71
IS COREVALVE A COST-EFFECTIVE TREATMENT FOR PATIENTS WITH 
SEVERE AORTIC STENOSIS WHO SATISY ALL THE CRITERIA FOR 
CONVENTIONAL AORTIC VALVE REPLACEMENT?
Eaton JN, Mealing S, Watt M, Sculpher M
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition; the treatment 
of which involves open surgery and cardiopulmonary bypass to replace the damaged 
aortic valve (AVR). AVR is invasive and carries a signiﬁ cant risk for patients with a 
high risk of perioperative mortality. Transcatheter aortic valve implantation using 
“CoreValve,” is less invasive, allowing for the percutaneous implantation of a replace-
ment valve in this patient group. However, the acquisition cost of CoreValve is greater 
than AVR, therefore it is important to assess whether CoreValve is a cost-effective 
alternative. METHODS: A 20-year Markov model was developed in Microsoft Excel. 
Treatment options were CoreValve and AVR with parameters derived from published 
literature. Both products were assumed to have the same long term impact on mortal-
ity. All costs were taken from the most recent published sources. Decrements were 
applied to age-speciﬁ c EQ-5D population norms to generate QALYs. Extensive proba-
bilistic and deterministic sensitivity analyses were performed to identify key cost-
effectiveness drivers. All costs and beneﬁ ts were discounted at 3.5% p.a. RESULTS: 
The model was very sensitive to changes in the short-term relative risk (RR) of mortal-
ity. In the base-case a short term RR of 0.57 was estimated from the available litera-
ture, the ICER was £25,229. However, the short-term mortality estimate for AVR 
was highly uncertain. Assuming a 0.75 RR the ICER is £34,603 and at 1.0 the ICER 
is £81,011. The model was also highly sensitive to changes in long term RR, device 
cost and time horizon. Assuming a threshold value of £30,000 per QALY gained, the 
probability that CoreValve is cost-effective is 0.54. CONCLUSIONS: Assuming that 
the RR of short-term mortality is at least 0.67 CoreValve is a cost-effective alternative 
for the treatment of severe AS in high risk patients.
PCV72
COST-EFFECTIVENESS OF EXTENDED-RELEASE NICOTINIC ACID/
LAROPIPRANT AS MONOTHERAPY VERSUS EZETIMIBE 
MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDAEMIA IN 
SCOTLAND
Jameson K1, Davies GM2, Ambegaonkar BM3, Sazonov V3, O’Regan C1
1MSD Ltd., Hoddesdon, UK; 2Merck & Co., Inc., Upper Gwynedd, PA, USA; 3Merck & Co., 
Inc., Whitehouse Station, NJ, USA
OBJECTIVES: Although statins are the mainstay of cholesterol management in Scot-
land, there remains a group of patients who are ineligible for such treatment due to 
contraindication or intolerance. This analysis estimates the cost-effectiveness of 
extended-release nicotinic acid/laropiprant 2 g/40 mg (ERN/LRPT), versus ezetimibe 
10 mg, as monotherapy for the treatment of mixed dyslipidaemia in Scotland in 
patients not currently receiving statin therapy. METHODS: The analysis was based 
on a previously published Markov model. Risk equations, based on the Framingham 
Heart Study, were used to model CHD-event rates in patients with established CHD, 
diabetes mellitus (DM) or a 10-year CHD-risk ≥20%. The model was run on a cohort 
of 2976 patient proﬁ les extracted from the General Practice Research Database. All 
patients had abnormalities in low-density-lipoprotein cholesterol (LDL-C ≥ 
2.0 mmol/L), high-density-lipoprotein cholesterol (HDL-C < 1.0 mmol/L [men], 
1.2 mmol/L [women]) and triglycerides (TG > 1.7 mmol/L). ERN/LRPT efﬁ cacy data 
were taken from the results of a published clinical trial, and ezetimibe data taken from 
a meta-analysis of monotherapy trials. Results were reported as the cost per quality-
adjusted life-year (QALY) gained. RESULTS: When compared to the use of ezetimibe, 
ERN/LRPT led to an increase in both QALYs and costs across the three patient-risk 
sub-groups. In patients with CHD, the base-case analysis estimated an incremental 
cost-effectiveness ratio (ICER) of £7559. Base-case results in patients with DM and 
patients facing a 10-year CHD risk ≥20% were £9,361 and £11,980, respectively. 
ICERS in the majority of sensitivity analyses did not vary by more than +/− £3000 
from the base case. CONCLUSIONS: When compared to ezetimibe, ERN/LRPT is 
projected to be cost-effective for the management of lipids in patients for whom the 
addition of statin is inappropriate or not tolerated, as reﬂ ected in the guidance issued 
by the Scottish Medicines Consortium.
PCV73
ECOMOMIC EVALUATION OF COMBINATION THERAPY FOR 
HYPERTENSION IN HIGH RISK PATIENTS IN SWEDEN
Brown R,1 Brede Y,3 Getsios D,2 Tambour M,4 Falvey H3
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Lexington, 
MA, USA, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Sverige AB, Taby, Sweden
OBJECTIVES: The ACCOMPLISH trial demonstrated that an ACEi/CCB combina-
tion (benazepril/ amlodipine) signiﬁ cantly reduced cardiovascular events in high risk 
hypertension patients compared to an ACEi/HCTZ combination (benazepril/ hydro-
chlorothiazide). ACCOMPLISH trial was the ﬁ rst to compare ﬁ xed dose combination 
therapies and examine longer term outcomes in this patient population. This study 
evaluated health and economic outcomes based on robust ﬁ ndings from ACCOM-
PLISH, and extended this analysis to an ARB/CCB combination (valsartan /amlodip-
ine). METHODS: ACCOMPLISH evaluated over 11,500 patients with hypertension 
at high risk for cardiovascular events. Trial data on cardiovascular events, diabetes, 
and renal failure endpoints, compliance and dosing levels were used to populate a 
compartmental cohort model which followed patients over 4 years. Cost data from 
Sweden (reported in 2008 Euros) were assigned to acute events and follow-up care, 
as well as hypertension-related treatment. a dose equivalency analysis of valsartan and 
benazepril was used to assign appropriate drug costs for the extension of the analyses 
to valsartan/amlodipine. The daily cost of benazepril/hydrochlorothiazide was c0.21, 
c0.16 for benazepril/amlodipine, and ranged between c0.90 and c1.10 for valsartan/
amlodipine, depending on dose. All outcomes were discounted at 3% per annum. 
RESULTS: Total costs over 4 years averaged c4554 per patient on benazepril/hydro-
cholorothiazide. With a lower drug cost and 45 fewer acute events per 1000 treated 
patients, costs were c322 lower per patient on benazepril/amlodipine. Assuming same 
outcome as for benazepril/amlodipine, valsartan/amlodipine was associated with 
incremental drug costs of c963 per patient, and c693 in overall costs, resulting in a 
cost per event avoided of c15,543. CONCLUSIONS: Based on the results of ACCOM-
PLISH, the combination of benzepril/amlodipine is clearly preferable to benazepril/
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hydrochlorothiazide. Using the ACCOMPLISH results for valsartan/amlodipine, it is 
likely to have reasonably low costs per event avoided for the treatment of high risk 
patients with hypertension in Sweden.
PCV74
ONE-YEAR COST-EFFECTIVENESS OF CYTOCHROME P450 2C19 
GENOTYPE-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH 
ACUTE CORONARY SYNDROMES IN THE UNITED KINGDOM
Charland SL1, Agatep B1, Malone D2, Stanek E1
1Medco Health Services, Inc., Bethesda, MD, USA; 2University of Arizona, Tucson, AZ, USA
OBJECTIVES: Cytochrome P450 2C19 (CYP2C19) genotype has been shown to 
affect cardiovascular (CV) outcomes for clopidogrel but not prasugrel. This study 
evaluates the incremental cost-effectiveness ratio (ICER) of CYP2C19-guided vs. 
routine antiplatelet therapy in acute coronary syndrome (ACS) patients in the UK. 
METHODS: We constructed a literature-based, decision analytic, Markov model to 
estimate the annual cost-effectiveness of CYP2C19-guided aspirin plus either clopido-
grel or prasugrel therapy vs. no genotyping. Post-initial ACS CV events were based 
on the TRITON-TIMI 38 study and genetic substudy. Cost data sources were: 
National Health Service (NHS) reference cost for 2008–09—nonfatal MI and stroke, 
CV death, intracranial hemorrhage, other life-threatening bleed, and minor bleed; 
Drug Tariff 2009—drugs; www.genetic-health.co.uk/—CYP2C19 genotyping; or US-
based reference pricing converted to £ using appropriate exchange rates -monthly CV 
disease maintenance cost. Disease-state utilities were obtained from published sources. 
The model allowed for clopidogrel/prasugrel discontinuation and aspirin monother-
apy. Model sensitivity was assessed using 1-way analysis of parameters varied by 
quartile or at least +/− 25%. RESULTS: The analysis demonstrated an increase in 
incremental cost (£81); greater incremental QALY (0.05); and an ICER £1529/QALY 
for CYP2C19 genotype-guided therapy over 12 months. The model was most sensitive 
to monthly CV care cost, NFMI cost, proportion of patients on clopidogrel, and life-
threatening bleeding cost. The model was least sensitive to the cost of clopidogrel, 
prasugrel, or CYP2C19 genotyping. CONCLUSIONS: The model-based ICER of 
£1,529/QALY for the CYP2C19 testing strategy is signiﬁ cantly less than the UK 
threshold of £20,000 that is considered good value. CYP2C19 genotype-guided clopi-
dogrel or prasugrel therapy is cost-effective for up to 1 year in ACS patients in the 
UK.
PCV75
CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE 
VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH 
PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION
Nilsson J1, Åkerborg Ö1, Lindgren P1, Bascle S2
1i3 Innovus, Stockholm, Sweden; 2Sanoﬁ -Aventis, Paris, France
OBJECTIVES: Dronedarone is a novel anti-arrhythmic drug (AAD) that, unlike other 
AADs, was shown to reduce cardiovascular hospitalizations or death in the ATHENA 
clinical trial. In addition, dronedarone reduces AF recurrence, maintains rate control, 
and has a favorable safety proﬁ le with low pro-arrhythmic and organ-toxicity proﬁ le. 
The objective of this study was to construct a health economic model to assess the 
cost-effectiveness of dronedarone vs. other AADs in a Canadian setting. METHODS: 
A state transition model evaluated through patient-level simulation has been developed 
using Microsoft Excel. It allows comparisons over varying time horizons and treat-
ment durations, and consists of health states for: treatment, off treatment, symptom-
atic AF recurrences, stroke, acute coronary syndromes, coronary heart failure and 
death. Transition probabilities were derived from the patient level data from the 
ATHENA trial, and relative risks between dronedarone and three commonly used 
comparators (amiodarone, sotalol and ﬂ ecainide) identiﬁ ed by clinical experts were 
derived from a mixed treatment comparison (systematic review) of published clinical 
trials published between 1980 and 2009. Patients discontinuing treatments were 
assumed to progress according to the rates in the standard of care arm of ATHENA. 
Costs of monitoring and initiation were taken into account. Costs were applied to 
each adverse event (AE) observed (Canadian Costs [C$] 2007). Effectiveness was 
expressed as QALYs, using preference based utility weights for health states based on 
published data. Discounting was 5% and a lifetime horizon was taken. RESULTS: 
The model predicts higher quality adjusted survival for patients on dronedarone: 
between 1.13 and 2.01 QALYs depending on comparator. In Canada, the resulting 
ICERs (per QALY) are C$5600 compared to amiodarone, C$5300 compared to ﬂ e-
cainide, and C$5300 compared to sotalol. Results were sensitive to differences in risk 
of mortality between treatment groups. CONCLUSIONS: Dronedarone represents a 
cost-effective treatment for patients with atrial ﬁ brillation in Canada.
PCV76
COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE IN PATIENTS 
WITH ATRIAL FIBRILLATION IN MEXICO: A WITHIN TRIAL ANALYSIS 
BASED ON ATHENA TRIAL
Martinez E1, Lemus A2, Soto H3
1Cardiology Hospital CMN Siglo XXI, Mexico City, D.F., Mexico; 2Sanoﬁ -Aventis, D.F., 
Mexico City, Mexico; 3ESEA, Mexico City, D.F., Mexico
OBJECTIVES: To perform a cost-effectiveness analysis (CEA) for the use of droneda-
rone in patients with atrial ﬁ brillation (AF) in order to prevent hospitalizations due 
to cardiovascular events or death (HCED), from the public health care system perspec-
tive in Mexico. METHODS: A CEA was made based on the clinical information from 
the multicenter, randomized, clinical study ATHENA, where dronedarone was com-
pared to placebo on top of standard treatment in patients with AF. Overall, 2301 
patients were randomized to dronedarone, and 2327 to placebo. The primary clinical 
endpoint was HCED. Only direct medical health care costs were calculated. The health 
resource utilization was elicited from the ATHENA trial. The unit costs of each event 
were obtained from the medical literature and/or validated by local experts, whenever 
information was not available. Most of the cost information is based on IMSS (Social 
Security) ﬁ gures, and updated to year 2009 (1c = MX$17.05). a discount rate of 5% 
was used. An incremental cost-effectiveness analysis was performed complemented by 
a deterministic sensitivity analysis (DSA) to assess robustness of the model. RESULTS: 
Patients randomized to dronedarone experienced 1190 events of HCED (average rate 
0.51 [CI 95%: 0.47–0.55]) while patients in the placebo group had 1601 (average 
rate 0.69 [CI 95%: 0.64–0.74]), or −415 events, 18% less hospitalizations (CI 95%: 
12–25%) for the dronedarone group. The average cost per patient in the dronedarone 
group was c3028 as compared to the placebo group of c2,941, yielding a cost differ-
ence of c87.4, and an avoided incremental cost per HCED of c477.00 of dronedarone 
vs. the placebo group. The DSA shows the analysis is robust. CONCLUSIONS: 
According to the ATHENA trial, dronedarone is a cost-effective treatment option for 
the reduction of HCED from the Mexican perspective. Dronedarone’s value could be 
enhanced if indirect costs averted from the decreased rates of HCED included.
PCV77
A SIMULATION MODEL TO ASSESS COST-EFFECTIVENESS OF STATINS 
IN HIGH RISK PATIENTS WITH ELEVATED LDL-C IN SPAIN
Darba J1, Restovic G2, Kaskens L2, Tunceli K3, Plans P4
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain; 3Merck, 
Whitehouse Station, NJ, USA; 4Generalitat de Catalunya, Barcelona, Spain
OBJECTIVES: The aim of this study is to estimate cost-effectiveness of lowering low-
density lipoprotein cholesterol (LDL-C) with statin monotherapy in patients with 
elevated LDL-C with two or more cardiovascular risk factors or either coronary heart 
disease (CHD) in Spain. METHODS: A Markov model was developed to represent 
the transition of a cohort of patients with elevated LDL-C or with CHD at risk of a 
cardiovascular event (CVE) through four health states: patients with LDL-C, CVE, 
death by CVE and death by other causes. Probabilities of a CVE in females and males 
were determined, based on CHD risks estimated trough locally-adjusted Framingham 
risk equations using data from the DORICA and PRIMULA study. LDL-C lowering 
efﬁ cacy of statins, mortality, and health-state utilities were obtained from published 
scientiﬁ c literature. Cardiovascular risk factors included were age, systolic blood pres-
sure, diabetes, smoking and high-density lipoprotein cholesterol (HDL-C). Treatment 
and CVE direct medical costs were obtained from a medication database and DRGs 
for public hospitals in 2009 in Spain. Deterministic results were estimated and a 
probabilistic sensitivity analysis was conducted. Results were expressed as expected 
cost per quality adjusted life-years (QALYs) gained. RESULTS: In deterministic analy-
ses, expected costs per patient per year at age of 40 were higher for patients with 2 
or more cardiovascular risk factors who were not treated than those who were treated 
(female: c41,300 vs. c40,106; male: c22,160 vs. c18,333). Effectiveness was higher 
for treated patients in both genders (female: 0.17 QALY; male: 0.37 QALY). Similar 
results were found for patients with CHD (female: c35,706 vs. c34,664, 0.10 QALY; 
male: c16,892 vs. c16,073, 0.12 QALY). CONCLUSIONS: From the perspective of 
the Spanish health care system, treatment with statin monotherapy is considered to 
be cost-effective versus no treatment in female and male patients with 2 or more risk 
factors or CHD.
PCV78
COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC 
STABLE ANGINA PATIENTS IN AN AUSTRIAN SETTING
Schwarz B1, Wild R2
1Center for Public Health, Medical University Vienna, Baden bei Wien, Austria; 2Servier 
Austria GmbH, Vienna, Austria
OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁ able cardiovascular risk factor. Ivabradine (ProcoralanÒ) is a speciﬁ c HR lower-
ing agent. This study aimed estimating the cost-effectiveness of ivabradine in stable 
angina patients with a normal sinus rhythm and a resting HR above 70 beats per 
minute (bpm) from the Austrian health care perspective: 1) versus generic diltiazem 
when beta-blockers (BB) are contra-indicated or non tolerated; and 2) in combination 
with generic atenolol versus generic atenolol alone. METHODS: A Markov chain 
Monte Carlo stochastic simulation model was used to estimate the inﬂ uence of HR 
lowering in cardiovascular morbidity and mortality and its economic consequences. 
Treatments considered are ivabradine, 7.5 mg twice a day, diltiazem, 240 mg once a 
day and atenolol 50 mg once a day. HR distribution, survival and time to hospitaliza-
tion were modelled as weibull functions. Events considered were acute myocardial 
infarction, stroke, heart failure, death and revascularization procedures. Only direct 
medical costs were included. Effectiveness was measured in quality-adjusted life-years 
(QALYs). Time horizon was set at 20 years and discount rates for costs and effective-
ness were 3%/year. RESULTS: The between-group difference in HR reduction was 
−6.4 bpm and −8.8 bpm in favour of ivabradine strategy in targeted patient popula-
tions 1) and 2) respectively. Incremental ivabradine strategy cost was c6789 versus 
generic diltiazem and c6749 versus generic atenolol. Incremental QALYs were 1.067 
and 1.076 respectively. Incremental cost-effectiveness ratios for ivabradine strategy 
were c5800/QALY and c6273/QALY. Deterministic sensitivity analyses showed that 
